Beyond Survival: Readmissions and Late Mortality in Pediatric ECMO Survivors
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Oct 2020 · 1 min read
In brief
In brief
Population-based study of 924 pediatric ECMO survivors across 10 states reveals 35.6% experienced unplanned readmission within one year, with 3% mortality during readmission. Risk factors for readmission and late mortality include ECMO indication, complex chronic conditions, transfer status, and discharge destination, highlighting the need for enhanced post-discharge surveillance in this vulnerable population.
Written by the GCMD Library team from the article.
Abstract
Introduction
The objective of our study was to identify rates of readmission and late mortality in pediatric extracorporeal membrane oxygenation (ECMO) patients after discharge from their ECMO hospitalization.
Methods
We conducted a population-based retrospective cohort study of children who were discharged after ECMO. Data were obtained from the State Inpatient Databases for 10 states. Time-to-event analyses were used to estimate the risk of readmission and to identify factors predictive of readmission and late mortality, including characteristics of initial hospital course and ECMO center volume.
Results
A total of 1603 pediatric ECMO patients were identified, and 42.4% of these patients died prior to discharge. Of the 924 ECMO survivors, 35.6% had an unplanned readmission, and 3% died during readmission within 1 year. The risk of readmission was significantly related to the indication for ECMO, number of complex chronic conditions, transfer status, and discharge destination (all p<0.05). The risk of late mortality was significantly related to health insurance, transfer status, number of complex chronic conditions, and indication for ECMO (all p<0.05).
Conclusions
Pediatric ECMO survivors have a high risk of hospital readmission with approximately 3% mortality during readmissions within 1 year of initial discharge.
Type of Study
Retrospective Cohort Study
Level of Evidence
Level III